Table 1.

Select Treatment Trials Targeting RAS

Drug Name	Mechanism of Action	NCT Number	Title	Study Population	Targeted Enrollment	Study Design	Primary Outcome Measure
Losartan	Anti-RAS	NCT04312009	Losartan for Patients With COVID-19 Requiring Hospitalization	Age ≥18 yrs with presumptive positive laboratory test for SARS-CoV-2; admission to the hospital with a sequential organ failure assessment score ≥1 and increased oxygen requirement; randomization within 24 h of presentation	200	Randomized, double-blind, placebo controlled	Difference in oxygenation status at 7 days
Losartan	Anti-RAS	NCT04311177	Losartan for Patients With COVID-19 Not Requiring Hospitalization	Age ≥18 yrs with presumptive positive laboratory test for SARS-CoV-2 or URI or fever	516	Randomized, double-blind, placebo controlled	Hospital admission up to 15 days

For an up-to-date listing of trials, search for “COVID-19” at the ClinicalTrials.gov website.

COVID-19 = coronavirus disease-2019; NCT = national clinical trial; OFA = organ failure assessment; RAS = renin-angiotensin system; SARS-CoV-2 = severe acute respiratory syndrome coronavirus-2; URI = upper respiratory infection.